5PSQ-066 Experience of use of axitinib in clinical practice

BACKGROUND: Axitinib is a potent and selective tyrosine kinase inhibitor of vascular endothelial growth factor receptors (VEGFR)−1, VEGFR-2 and VEGFR-3. These receptors are implicated in pathologic angiogenesis, tumour growth and metastatic progression of cancer. Axitinib has been shown to potently...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Eur J Hosp Pharm
Asıl Yazarlar: Miralles, P, Gutierrez, L Soriano, Ambrosio, V de Pedro, Niebla, M Cruel, Ferrer, G Molas, Contel, A Pérez
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BMJ Group 2018
Konular:
Section 5: Patient safety and quality assurance
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535475/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.420
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller